MedTrace Logo

Ripretinib (QINLOCK®) According to Current SmPC

NCT06619275 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2025-12-05

No results posted yet for this study

Summary

The goal of this prospective, observational study INTEREST is to collect real-world data on ripretinib treatment in a broad patient population in Germany. Ripretinib will be administered according to the current SmPC. Thus, INTEREST will evaluate for the first time ripretinib in GIST patients in a real-world setting in Germany.

The main questions the study aims to answer are:

* Evaluate quality of live (QoL) using the questionnaire EQ-5D-5L to gain knowledge about how ripretinib treatment affects GIST patients' well-being (change compared to Baseline, Time to Deterioration)
* Assessment of effectiveness in routine treatment (Progression-Free Survival, Overall Survival, Best Response, Overall Response Rate, Disease Control Rate
* Assessment of drug safety
* Assessment of parameters of physicians\' treatment decision making
* Description of treatment reality in detail

Conditions

  • GIST - Gastrointestinal Stromal Tumor

Interventions

DRUG

Ripretinib

Switch-Control Tyrosine Kinase Inhibitor

Sponsors & Collaborators

  • Deciphera Pharmaceuticals (Switzerland) AG

    collaborator UNKNOWN

  • iOMEDICO AG

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-17
Primary Completion
2025-08-15
Completion
2025-09-15

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06619275 on ClinicalTrials.gov